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Hepatitis C virus (HCV) infection is a major cause of chronic
liver disease including liver cirrhosis and hepatocellular carci-
noma [1]. The current antiviral therapy is characterized by lim-
ited efﬁcacy, high costs, and substantial side effects. A vaccine
for the prevention of HCV infection is not available. Thus, novel
strategies for the prevention and treatment of HCV infection
are urgently needed (for a review see [1,2]). The development
of efﬁcient antiviral treatments and vaccines has been hampered
by the lack of a convenient small animal model for HCV infection.
Although HCV has been shown to enter into mouse cell lines
expressing human HCV receptors [3], mouse hepatocytes are
unable to produce infectious HCV infection [4]. Over the past
two decades the chimpanzee has been commonly used to study
mechanisms of acute and chronic HCV infection (for review see
[21]). These studies have enormously contributed to our current
understanding of HCV infection [5] as well as the preclinical eval-
uation of antivirals [6]. However, the chimpanzee model is char-
acterized by limited availability, high costs, and important ethical
restrictions. Furthermore, hepatocytes of the tree shrew Tupaia
belangeri are susceptible to HCV infection [8]. However, viral load
in infected animals is low [9].
The discovery of a hepatocyte-lethal phenotype in mice carry-
ing a urokinase-type plasminogen activator transgene controlled
by an albumin promotor (Alb-uPA) with the reconstitution of liv-
ers of those mice with xenografted rat hepatocytes [10] has laid
the foundation for the development of small animal models of
infection with hepatitis B and C viruses using xenografted pri-
mary human hepatocytes (PHH) (for review see [7]).
The uPA-xenograft model had been ﬁrst established for the
development of a hepatitis B mouse model by transplanting
woodchuck or PHH into Alb-uPA mice on an immunodeﬁcient
recombination activating gene 2 knock-out (Rag-2/) back-
ground. Repopulating woodchuck hepatocytes in Alb-uPA/rag-2Journal of Hepatology 20
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(T.F. Baumert).mice, which lack mature B and T lymphocytes, allowed produc-
tive infection with woodchuck hepatitis B virus [11]. Subse-
quently, Mercer and colleagues demonstrated that the
severe combined immunodeﬁciency disorder (SCID-beige)/Alb-
uPA mouse engrafted with PHH can be infected with HCV
in vivo [12]. A further development of this model is a system that
can be regulated for repopulating the liver of immunodeﬁcient
mice, based on mice lacking the fumaryl acetoacetate hydrolase
[Fah], recombination activating gene 2 [Rag-2/], and the
gamma-chain of the receptor for IL-2 [Il-2rgamma or cc] (Fah/
Rag-2//cc/ model). Oral administration of a small molecule
(NTBC) prevents the accumulation of hepatotoxic metabolites
resulting from the Fah deﬁciency. By regulating hepatotoxicity
using NTBC, this model allows for transplantation of PHH at
any age, which may improve robustness of engraftment and
mortality [13].
Although all chimeric mouse models are characterized by the
absence of a functional immune system [7], they are very useful
for the study of HBV and HCV infection in vivo as well as for the
evaluation of antivirals targeting the virus or essential host fac-
tors present in transplanted hepatocytes [14,15]. The hepato-
cyte-lethal phenotype of these models allows for transplanting
immunodeﬁcient mice with PHH by intrasplenic injection. Suc-
cessful engraftment of hepatocytes is monitored by quantiﬁca-
tion of human albumin concentrations in the plasma or
serum. For uPA-transgene models, the transplantation is usually
performed within the ﬁrst two weeks of life and human albu-
min levels are determined at least three weeks after transplan-
tation. If the liver repopulation reaches a threshold level, human
liver chimeric mice can then be infected by HBV [16] or HCV
[12].
Nevertheless, the wide-spread use and further development of
these model systems are hampered by the complexity of their
set-up, essentially for technical reasons. One limitation is the
availability of high quality PHH, but the major obstacles are the
technical challenges to achieve high repopulation of the chimeric
mouse liver with human hepatocytes. Interestingly, several inde-
pendent studies have shown that the level of liver repopulation
required for HCV infection is signiﬁcantly higher than that
required for HBV infection: while 15% liver parenchyma replace-
ment by PHH is sufﬁcient to support a HBV infection [16], at least
50% replacement is needed to support a HCV infection [12]. Thus,
the identiﬁcation of technical or biological parameters allowing10 vol. 53 j 421–423
Fig. 1. Virus and host factors inﬂuencing the survival, PHH engraftment and
permissiveness for HCV infection in the uPA-SCID model, as identiﬁed by
Vanwolleghem and colleagues [17]. The factors positively inﬂuencing the
transplantation of PHH into upA-SCID mice and permissiveness for HCV infection
are circled. Abbreviations: HCV, hepatitis C virus; PHH, primary human
hepatocytes.
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efﬁcient engraftment of permissive PHH is of crucial importance
for the improvement of the model, in particular for robust infec-
tion with HCV.
To identify essential viral and host factors for successful
engraftment of HCV permissive hepatocytes, the Leroux–Roels
laboratory at Ghent University, Belgium, has performed a com-
prehensive functional analysis of a large series of animals which
is published in this issue of the Journal [17]. In this study, per-
formed by one of the most experienced laboratories in the ﬁeld,
animal survival, engraftment efﬁcacy, kinetics of liver repopula-
tion, and viral infection was analyzed in 400 transplanted chime-
ric upA-SCD mice.
First, Vanwolleghem and colleagues [17] demonstrated that
the ﬁrst 7 days after transplantation are the most critical period
for survival. This period is characterized by frequent identiﬁca-
tion of necrotic donor hepatocytes in portal vein branches and
periportal sinusoids. The necrosis tended to be more extensive
in mice transplanted with PHH than with murine hepatocytes,
the latter repopulating the liver approximately four-times faster
than the former donor cells after this critical period.
Peri-operative problems and the use of fresh PHH were iden-
tiﬁed as independent negative risk factors for survival of the host.
Since fresh and frozen PHH led to similar engraftment levels, both
in terms of fraction of engrafted mice and human albumin levels,
cryopreserved PHH are superior to fresh PHH regarding the ﬁnal
outcome of permissive chimeric mice. Engraftment level seemed
to be mainly donor-dependent, with commercially available fro-
zen PHH again being the best source of PHH in this series. Inter-
estingly, donor age and PHH viability were not predictors of
successful engraftment (Fig. 1).
The quality of the viral inoculum is another important factor for
successful infection. The use of serum-derived HCV has been
reported to provide higher HCV plasma titers than infection with
cell culture-derived recombinant HCV [14]. Vanwolleghem and
colleagues demonstrate that viral load and proper conservation
and storage of the inoculum are crucial for successful infection
[17]. Serial freezing/thawing cycles clearly impair the infectivity
of the inoculum. In this regard, it is of interest tonote, that the same
laboratory has characterized and titrated reference genotypes 1–6
HCV batches frompooled sera of chronically infected chimpanzees
in uPA-SCIDmice in collaborationwith the Laboratoryof Infectious
Diseases, National Institutes of Health, Bethesda [18].
Most importantly, this comprehensive analysis allowed the
identiﬁcation of criteria for HCV infection with 100% success rate
(Fig. 1). These criteria include (i) serum human albumin level
>1 mg/ml at time of HCV injection and during the course of the
experiment and (ii) a HCV inoculum containing >104 IU HCV RNA
with no more than one freeze–thaw cycle [17]. The human albu-
min threshold of 1 mg/ml deﬁned in the present study is similar
to the one suggested by Mercer et al. [12] using the same model.
Higher levels have been reported to be required by another labora-
tory using the uPA-SCID model [19] or in the Fah/Rag-2//cc/
model [14]. Standardization of the sampling method (plasma ver-
sus serum) and human albumin quantiﬁcationmethod and amore
accurate correlation between human albumin concentrations and
liver replacement index could help in clarifying these apparent dif-
ferences. Interestingly, improved PHH engraftment was obtained
in the Fah/Rag-2//cc/ model by increasing the PHH dose up
to 3–5  106 injected cells [14], instead of 0.5–1  106 PHH in
the uPA-SCID model. Whether increasing the PHH number in the
uPA-SCID model would also improve the engraftment level422 Journal of Hepatology 201remains to be determined. An important difference between the
two models is the fact that the uPA-SCID mice requires transplan-
tation at a young age (at approximately three weeks of age), while0 vol. 53 j 421–423
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adult Fah/Rag-2//cc/ mice can be transplanted at a later age,
probably injecting a higher number of PHH. Further differences
between the inducible (Fah/Rag-2//cc/) and the uPA-SCID
model are related to the increased expression of uPA in the latter.
uPA transforms proHGF to its active form HGF, activates plasmin-
ogen, and promotes liver matrix proteolysis during repair, a series
of processes that may promote the successful engraftment and
proliferation of PHH [20].
Although additional studies are required to better understand
the biochemical and biological mechanisms involved in PHH
engraftment, the identiﬁcation of host and viral factors required
for engraftment of permissive hepatocytes by Vanwolleghem
and colleagues [17] will be very helpful to apply and further
develop humanized mouse models for HBV and HCV infections.
Thus, the results of this thorough and comprehensive study will
be very useful for laboratories using and advancing the current
humanized mouse models e.g. by approaches to reconstitute a
human immune system. Furthermore, this study may be also of
interest for teams aiming to set-up this important in vivo model
for the study of HBV and HCV infection. The further development
as well as a more wide spread use of humanized mouse models
will advance our knowledge of virus–host interactions and the
development of urgently needed novel efﬁcient antivirals.Conﬂict of interests
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